National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
NCI Drug Dictionary
Page Options
Print This Page  Print This Page
Quick Links
Director's Corner
Updates from the Director

Dictionary of Cancer Terms
Cancer-related terms

NCI Drug Dictionary
Definitions, names, and links

Funding Opportunities
Research and training

NCI Publications
Order/download free booklets

Advisory Boards and Groups
Information, meetings, reports

Science Serving People
Learn more about NCI

Español
Información en español
NCI Highlights
Virtual and Standard Colonoscopy Both Accurate

NCI Responds to Hurricanes

The Nation's Investment in Cancer Research FY 2009

Cancer Trends Progress Report: 2007 Update

Past Highlights
You CAN Quit Smoking Now!
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

inosine dialdehyde
A toxic purine analogue. Inosine dialdehyde inhibits ribonucleotide reductase, resulting in decreased synthesis of DNA, RNA, and proteins, and G2/M-phase cell cycle arrest. This agent also forms stable covalent crosslinks in proteins, thereby inhibiting the activity of enzymes involved in nucleic acid synthesis. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:diglycoaldehyde
INOX
Abbreviation:IdA
Code name:Wy-5321
Chemical structure names:
  • 9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R-(R*, R*))- (9CI)
  • 9H-purine-9-acetaldehyde, alpha-(1-formyl-2-hydroxyethoxy)-1,6-dihydro-6-oxo-, (R,R)- (8CI)
  • diglycolaldehyde, alpha-(hydroxymethyl)-.alpha.'-(6-hydroxy-9H-purin-9-yl)



Previous:infliximab, Infumorph, ingenol 3-angelate, Innohep, INO-1001
Next:inositol, inotuzumab ozogamicin, interferon alfacon-1, interleukin-12 gene, interleukin-2 gene

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov